ecteinascidin 743 has been researched along with er-086526 in 20 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (er-086526) | Trials (er-086526) | Recent Studies (post-2010) (er-086526) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 567 | 113 | 517 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Hanlon, LH | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Trendowski, M | 1 |
| Newman, DJ | 1 |
| Carbini, M; Maki, RG; Pang, A | 1 |
| Azvolinsky, A | 1 |
| Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V | 1 |
| Patel, SR; Ratan, R | 1 |
| Araki, N; Kawai, A; Takahashi, S; Ueda, T; Yonemori, K | 1 |
| Amadori, D; Bongiovanni, A; Casadei, R; De Vita, A; Fausti, V; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Pieri, F; Recine, F; Riva, N; Spadazzi, C | 1 |
| Costa-Lotufo, LV; Jimenez, PC; Wilke, DV | 1 |
| Abaricia, S; Hirbe, AC | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Baldi, GG; Gronchi, A; Suarez-Kelly, LP | 1 |
| Blay, JY | 1 |
| Bauermeister, A; Branco, PC; Costa-Lotufo, LV; Gaudêncio, SP; Jimenez, PC; Rezende-Teixeira, P; Wilke, DV | 1 |
| Asanuma, K; Hagi, T; Nakamura, T; Sudo, A | 1 |
| Chittepu, VCSR; Gallardo-Velazquez, T; Kalhotra, P; Osorio-Revilla, G | 1 |
| Barisella, M; Brich, S; Casanova, M; Collini, P; Dagrada, GP; Doldi, V; Ferrari, A; Fiore, M; Frezza, AM; Gasparini, P; Gronchi, A; Pasquali, S; Percio, S; Stacchiotti, S; Tortoreto, M; Zaffaroni, N; Zuco, V | 1 |
11 review(s) available for ecteinascidin 743 and er-086526
| Article | Year |
|---|---|
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.
Topics: Antineoplastic Agents; Biological Products; Cytochalasins; Dioxoles; Diphtheria Toxin; Drug Discovery; Epothilones; Furans; Harringtonines; Homoharringtonine; Humans; Immunoconjugates; Interleukin-2; Ketones; Recombinant Fusion Proteins; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin; Withanolides | 2015 |
Developing natural product drugs: Supply problems and how they have been overcome.
Topics: Actinobacteria; Animals; Antineoplastic Agents; Biological Products; Dioxoles; Diterpenes; Ethers, Cyclic; Furans; Humans; Ketones; Macrolides; Oligopeptides; Porifera; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2016 |
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
Topics: Adult; Antineoplastic Agents; Dioxoles; Furans; Humans; Indazoles; Ketones; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2016 |
Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dioxoles; Drug Evaluation, Preclinical; Furans; Humans; Ketones; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Furans; Humans; Indazoles; Japan; Ketones; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2017 |
Marine drugs for cancer: surfacing biotechnological innovations from the oceans.
Topics: Antineoplastic Agents; Aquatic Organisms; Biotechnology; Brentuximab Vedotin; Cytarabine; Drug Development; Drug Discovery; Furans; Immunoconjugates; Ketones; Neoplasms; Oceans and Seas; Trabectedin | 2018 |
Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.
Topics: Antibodies, Monoclonal; Doxorubicin; Furans; Humans; Immunotherapy; Ketones; Liposarcoma, Myxoid; Mesoderm; Protein-Tyrosine Kinases; Trabectedin | 2018 |
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Drug Discovery; Drugs, Investigational; Furans; Humans; Ketones; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2019 |
Enriching cancer pharmacology with drugs of marine origin.
Topics: Animals; Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Cytarabine; Drug Discovery; Furans; Humans; Ketones; Neoplasms; Porifera; Trabectedin | 2020 |
9 other study(ies) available for ecteinascidin 743 and er-086526
| Article | Year |
|---|---|
Scientists are searching the seas for cancer drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Depsipeptides; Dioxoles; Ethers, Cyclic; Furans; Humans; Isoquinolines; Ketones; Macrolides; National Institutes of Health (U.S.); Oceans and Seas; Peptides, Cyclic; Seawater; Tetrahydroisoquinolines; Trabectedin; United States | 2006 |
In brief: Two Drugs for soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Furans; Humans; Ketones; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tubulin Modulators | 2016 |
Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.
Topics: Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Dioxoles; Disease-Free Survival; DNA-Binding Proteins; Furans; Humans; Indazoles; Ketones; Molecular Targeted Therapy; Mutation; Pyrimidines; Sarcoma; SMARCB1 Protein; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Transcription Factors | 2016 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.
Topics: Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Cycle Checkpoints; Dioxoles; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Furans; Gene Expression Regulation, Neoplastic; Humans; Ketones; Male; Patients; Primary Cell Culture; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2017 |
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Furans; Gemcitabine; Humans; Ifosfamide; Indazoles; Ketones; Liposarcoma; Middle Aged; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Trabectedin | 2019 |
Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Female; Furans; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Ketones; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis; Trabectedin; Treatment Outcome | 2020 |
Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
Topics: Catalytic Domain; Depsipeptides; Drug Repositioning; Furans; Humans; Ketones; Models, Molecular; Molecular Docking Simulation; Peptide Hydrolases; Peptides, Cyclic; Quantitative Structure-Activity Relationship; SARS-CoV-2; Serine Proteinase Inhibitors; Trabectedin; Viral Proteins; Virus Replication | 2021 |
Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft.
Topics: Antineoplastic Agents; Desmoplastic Small Round Cell Tumor; Heterografts; Humans; Irinotecan; Trabectedin | 2023 |